The Latest Cardiac and Vascular News
Sales growth of 13.8 percent; organic sales growth of 17.5 percent Global COVID-19 testing-related sales of $3.3 billion in the first quarter Excluding COVID-19 testing-related sales, first-quarter reported sales growth of 3.9 percent and organic sales growth of 7.7 percent GAAP diluted EPS growth of 37.0 percent; adjusted diluted EPS growth of […]
Abbott’s Aveir single chamber (VR) pacing system is the world’s only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement Aveir VR has an increased projected battery life that can be up to two times longer than other commercially available leadless pacemakers when using the […]
– New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS™ HF System, a small implantable sensor that can flag early warning signs of worsening heart failure – FDA approval was supported by data from the GUIDE-HF trial, which suggested that the CardioMEMS sensor […]
– Abbott’s investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart – Proprietary implant-to-implant (i2i™) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate – Aveir DR is also specifically […]
– Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent – Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter – Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent – Full-year 2021 sales growth of 24.5 […]
– EnSite™ X EP System with EnSite Omnipolar Technology (OT) provides a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise ABBOTT PARK, Ill., Jan. 12, 2022 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System […]
– Abbott included on DJSI for 17 consecutive years for strong environmental, social and governance (ESG) performance – Top score in the Health Care Equipment & Supplies sector reflects Abbott’s 2030 Sustainability Plan focus on innovating for greater access to life-changing technologies and breaking down barriers to health equity ABBOTT […]
— New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms — Abbott’s Aveir system is the world’s only leadless pacemaker specifically designed to be retrieved when the device needs to […]
– One in four physicians surveyed feel the “lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease” is a key obstacle to an accurate diagnosis – Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease […]
– Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent – GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent – Global COVID-19 testing-related sales were $1.9 billion in the third quarter – Excluding COVID-19 testing-related sales, third-quarter sales […]
